Human papillomavirus (HPV) is a group of non-enveloped, double-stranded DNA viruses strongly linked to various warts and precancerous lesions. High-risk HPV types are a primary cause of cervical cancer and other malignancies. Today, clinical screening for high-risk HPV increasingly relies on precise detection of type-specific DNA sequences, which is essential for early intervention and prevention.
On February 15, 2026, research teams from the Center for Advanced Analytical Science, Guangzhou Key Laboratory of Sensing Materials and Devices, Guangdong Engineering Technology Research Center for Sensing Materials and Devices, and the School of Chemistry and Chemical Engineering at Guangzhou University, in collaboration with the School of Chemical Engineering and Technology at Sun Yat-sen University, published a groundbreaking paper titled “Enzyme-linked lectin assay for amplified electrochemical detection of HPV DNA” in the leading journal Biosensors and Bioelectronics (Impact Factor: 10.5).
This innovative study introduces a highly sensitive electrochemical platform based on enzyme-linked lectin assay (ELLA) for amplified detection of high-risk HPV DNA, offering a powerful new tool for clinical screening.
Core Principles and Key Innovations
The research team developed a sophisticated, multi-step detection workflow:
- Target-Specific Capture: Complementary peptide nucleic acid (PNA) probes hybridize selectively with the target HPV DNA sequences. PNA probes are renowned for their exceptional sequence specificity and stability, capable of distinguishing even single-base mismatches.
- Phosphate-Zr(IV)-Carboxylate (PZrC) Crosslinking: Leveraging the strong coordination chemistry of Zr⁴⁺, carboxyl-functionalized disaccharide linkers are precisely anchored to every phosphate backbone site on the captured DNA. This site-specific modification— a core innovation—enables functionalization of multiple sites per target molecule, setting the stage for substantial signal amplification.
- Lectin-Disaccharide Affinity Recruitment: The disaccharide linkers are recognized with high affinity by specific lectins, which in turn recruit a large number of alkaline phosphatase (ALP)-conjugated lectins, achieving dense labeling.
- Enzymatic Deposition of Silver Nanoparticles (AgNPs): ALP catalyzes the substrate to generate abundant AgNPs that deposit on the electrode surface, dramatically enhancing the electrochemical signal.
By exploiting the PZrC strategy’s ability to decorate each phosphate site with a disaccharide (and thus recruit multiple ALP labels), the system delivers dual signal amplification: enzymatic cascade from multi-labeled ALP and electrochemical enhancement via AgNP deposition. This synergy dramatically boosts overall sensitivity.
Under optimized conditions, the method achieves an impressive detection limit of 0.24 fM for HPV16-specific DNA sequences, demonstrating exceptional sensitivity. The PNA probes also confer outstanding specificity, with robust discrimination against single-base mismatches. Furthermore, the platform was successfully validated for direct HPV DNA detection in serum samples, highlighting its strong potential for real-world applications.
Why This Technology Holds Great Promise
Compared to conventional PCR or hybridization-based approaches, this ELLA-based electrochemical platform offers several compelling advantages:
- Ultra-high sensitivity (reaching the femtomolar level)
- Excellent specificity (single-base resolution)
- User-friendly and rapid operation
- Minimal instrumentation requirements, ideal for point-of-care testing (POCT) and resource-limited settings
These features position the method as a highly promising tool for rapid screening of high-risk HPV infections, particularly in underserved regions, with significant potential for clinical translation.
Key Reagent Information
The PNA probe sequence used in the study is:
5′-SH-(CH₂)₆-TTA ACT GCA CTT CCA CTG TAT ATC-3′
supplied by SBS Genetech.
Since 2000, SBS Genetech has been dedicated to providing safer, higher-quality, and more cost-effective solutions to life science researchers worldwide. Our products serve leading teams in over 60 countries and are routinely cited in top-tier journals such as Science, Cell, Cancer Cell, and Cell Metabolism.
We are confident that through ongoing innovation and product refinement, SBS Genetech will continue to empower advancements in HPV screening, early cancer diagnostics, and broader molecular diagnostics, injecting fresh momentum into the field.
The emergence of this ELLA-based electrochemical detection technology may represent a significant milestone in advancing high-risk HPV molecular diagnostics toward greater sensitivity and accessibility. We look forward to further clinical validation and translational efforts, enabling this cutting-edge approach to benefit more people and support the progress of precision medicine.